Futures
Access hundreds of perpetual contracts
TradFi
Gold
One platform for global traditional assets
Options
Hot
Trade European-style vanilla options
Unified Account
Maximize your capital efficiency
Demo Trading
Introduction to Futures Trading
Learn the basics of futures trading
Futures Events
Join events to earn rewards
Demo Trading
Use virtual funds to practice risk-free trading
Launch
CandyDrop
Collect candies to earn airdrops
Launchpool
Quick staking, earn potential new tokens
HODLer Airdrop
Hold GT and get massive airdrops for free
Pre-IPOs
Unlock full access to global stock IPOs
Alpha Points
Trade on-chain assets and earn airdrops
Futures Points
Earn futures points and claim airdrop rewards
Regeneron’s Lunsekimig Data Expand Immunology Story Beyond Dupixent Dependency
Regeneron Pharmaceuticals (NasdaqGS:REGN) announced positive Phase 2 results for its bispecific antibody, lunsekimig, in treating moderate to severe asthma and chronic rhinosinusitis with nasal polyps, meeting primary and key secondary endpoints. This data represents a significant advancement for Regeneron’s immunology pipeline beyond its core product Dupixent, suggesting potential new revenue streams. While early-stage, these results strengthen the company’s long-term immunology strategy by reducing dependency on existing franchises and offering a new asset in competitive markets.